
Brain-Computer Interface enables movement for people who are paralysed
Researchers at the University of California, San Francisco (UCSF) have achieved a significant breakthrough in assistive technology for individuals with paralysis. The lead author of a scientific paper on the project, an Indian who grew up in Chennai, Nikhilesh Natraj, says they have developed a brain-computer interface (BCI) that allows a paralysed man to control a robotic arm simply by imagining the movements he wishes to execute.
Dr. Natraj is a neuroscientist and neural engineer at the Weill Institute for Neurosciences, UCSF. 'Here, our team has developed a framework that allows a paralysed man to control a robotic arm for 7 months straight using just his thoughts alone, with minimal calibration,' he says. The results of this study were published in a recent volume of the peer-reviewed journal Cell.
Developing stability in Brain-Computer Interfaces (BCIs)
To start with, the team had to understand the neural patterns behind movement. The key was discovering how activity shifts in the brain day to day as a study participant repeatedly imagined making specific movements. Once a machine learning/AI algorithm was programmed to account for those shifts, it worked for months at a time.
Karunesh Ganguly, professor of neurology and a member of the UCSF Weill Institute for Neurosciences who studied how patterns of brain activity in animals represent specific movements, saw that these patterns changed day-to-day. If one assumed that the same thing was happening in humans, these changes would explain why the participants' BCIs became unstable and quickly lost the ability to recognise movement patterns. The team worked with an individual who had been paralysed by a stroke and could not speak or move, a note on the varsity website stated.
The study participant had tiny sensors implanted on the surface of his brain that could pick up brain activity when he imagined moving. The sensors do not send pulses to the brain, but only read out the intent to move from the movement regions of the brain, Dr. Natraj explains.
AI and signal processing
To see whether and how his brain patterns changed over time, the participant was asked to imagine moving different parts of his body. Although he couldn't actually move, the participant's brain could still produce the signals for a movement when he imagined himself doing it. The BCI recorded the brain's representations of these movements through the sensors.
Analysing the patterns in the high-dimensional sensor data, the team found that while the structure of movement representations stayed the same, their locations in the high-dimensional data shifted slightly from day to day. By tracking these shifts and predicting how it would evolve, the team was able to overcome instability in BCI systems and developed an end-to-end signal processing and AI framework.
From imagined movements to real-world actions
The participant was then tasked with imagining himself making simple movements with his fingers, hands or thumbs while the sensors recorded his brain activity to train the AI. The read out signals were then decoded to actuate a robotic arm. Initially, he practiced on a virtual robot arm that gave him crucial feedback on the accuracy of his visualisations, helping him refine his direction and control.
Eventually, the participant managed to control a real-world robotic arm executing the action. He could perform tasks such as picking up and manipulating blocks, turning them, and relocating them. He even managed to open a cabinet, retrieve a cup, and hold it under a water dispenser—simple tasks but those that can be life-changing for those living with paralysis.
Having established that it can be done is the first stage, a lot more work needs to be put into refining the technique and for it to be deployed among people who have paralysis, Dr. Natraj says. Especially, the system should be able to work fluidly in complex scenarios with many distractions, such as when going to a crowded grocery store, he adds.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
20 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.


Time of India
an hour ago
- Time of India
Seminar on MBBS, global education pathways in Pune draws enthusiastic response
1 2 P une: A large gathering of aspiring students and parents attended an informative Mission Admission seminar organised by The Times of India jointly with The Astute Academy at Dr. Kalmadi Shamarao Junior College auditorium on Sunday. Conducted by Tushar Vinod Deoras, a former BARC scientist and chairman of Astute Academy, the seminar aimed to demystify the complexities of Indian and international admissions for MBBS and higher education. The first session focused on the Indian MBBS admission process, offering clarity for students with NEET scores as low as 200. Attendees also learned about affordable pathways to study medicine in the United States through structured Indo-American university collaborations. The second session delved into undergraduate and postgraduate admissions in the US and Germany. Parents and students were provided with detailed guidance on securing spots at prestigious universities abroad. During the first session, Deoras shared a wealth of information. He pointed out that many private medical colleges offer donation-free management quota merit seats. He explained fee structures, wherein funding is controlled by govt, and proposed to students tripartite Indo-American university partnered systems, which provide affordable, sophisticated modern medical education in the US and subsequently offer employer-relevant value around the globe. The second session was about undergraduate and postgraduate courses offered in the US and Germany, particularly emphasising on Ivy League schools and Germany's technical universities. Deoras noted how flexible and multidisciplinary the US system is, with more emphasis on career focus than rigid course structures. He urged students to start building their profiles as early as Std IX and to apply to international universities at least one year in advance, as most operate on a first-come, first-served basis. He said, "Quality education and a successful career are a student's fundamental right. Students and parents should not judge countries by stereotypes but understand which system aligns best with the student's goals." A highlight of the seminar was its interactive nature. One parent shared, "The session was very enlightening. Many doubts regarding my son's education were resolved, and I feel much more at peace now." Another participant raised a query about dentistry as a career path, to which Deoras responded that it remains an underappreciated but highly rewarding field in India. While initial years in practice may be challenging, dentistry offers significant long-term growth and financial prospects. Deoras also addressed several audience questions about state-wise admission quotas for MBBS, the application process for foreign universities, and the admission timelines and requirements for medical education abroad. The seminar concluded with a positive response from the audience who appreciated the transparency, practical guidance, and motivational approach.


Time of India
an hour ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.